Your Yourlocation: Home > Tiotropium bromide(136310-93-5) drug delivery device

The current market-leading drugs for COPD are tiotropium bromide(136310-93-5) and GlaxoSmithKline's Advair. Tiotropium was approved in 2002, but a 2011 study based on a combination of previous clinical trials provoked concern about the safety of this drug, the study showed that through the Respimat device to use tiotropium bromide Of patients had an increased risk of death of 52% compared with placebo. Boehringer Ingelheim and its marketing partner Pfizer at the time of the study to debate the results.

The new, three-year clinical trial found that Respimat was as safe as a HandiHaler inhaler, and that COPD patients using Respimat had an average of 756 days without symptoms of persistent worsening, compared with 719 days for patients using HandiHaler. New trials were not included in the placebo group.

Boehringer Ingelheim hopes the new, company-sponsored clinical trial, one of the largest of the current COPD trials, will dispel doubts about the product and reinforce the benefits of all tiotropium bromide(136310-93-5) preparations. Tiotropium bromide(136310-93-5) last year's global sales of 4.6 billion US dollars.

The test results are equally important for Boehringer Ingelheim's future development of new drug products, including its LABA / LAMA products, as they are also dependent on Respimat. The new study, sponsored by Boehringer Ingelheim, is also published in the New England Journal of Medicine.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved